Carpenter Technology Corporation (CRS)
Carpenter Technology: I Called The Sell, Now It's A Buy
Carpenter Technology is upgraded to Buy after a 36% price decline and improved free cash flow expectations. CRS's operating income is projected to grow 21%-25% by FY27, with FY29 targets of $1.2–$1.3 billion, driven by aerospace demand and capacity expansion. Free cash flow expectations have increased 20% due to strong cash conversion and lower CapEx, supporting a base case price target of $438.44 (14% upside).
After Plunging 13.0% in 4 Weeks, Here's Why the Trend Might Reverse for Carpenter (CRS)
The heavy selling pressure might have exhausted for Carpenter (CRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
What Makes Carpenter (CRS) a New Buy Stock
Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is CRS Set to Gain From Growth in Its Specialty Alloys Operations?
Carpenter Technology's Specialty Alloys Operations post record margins as productivity and product mix gains fuel growth and support ambitious profit targets.
Carpenter Technology Touts Record Fiscal 2026 Earnings, Capacity Expansion at Annual Meeting
Carpenter Technology NYSE: CRS said fiscal 2026 marked another record year for earnings, while the company continues to pursue a capacity expansion intended to support demand from aerospace and defense customers.
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has secured a South Korean patent for POLB 001 to prevent cytokine release syndrome (CRS) induced by cancer immunotherapy. CRS is a potentially serious complication of a range of cancer immunotherapies.
After Plunging 18.6% in 4 Weeks, Here's Why the Trend Might Reverse for Carpenter (CRS)
The heavy selling pressure might have exhausted for Carpenter (CRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Can Strong End-Market Demand Boost Carpenter Technology's Growth?
CRS sees strong aerospace demand and rising bookings supporting fiscal 2027 growth, with capacity expansion set to aid longer-term gains.
Can Carpenter Technology Sustain Its Strong Cash Flow Growth in FY27?
CRS delivers strong FY26 cash flow growth. It expects higher profitability and $400-$430M in adjusted free cash flow in FY27.
Will CRS's Brownfield Expansion Project Aid Growth Through 2029?
Carpenter Technology's $400M brownfield expansion is on track to boost capacity, supporting its $1.2-$1.3B FY29 operating income target.
CRS Earnings Beat Estimates in Q4 on Pricing, Shares Rise 7%
Carpenter Technology beats on Q4 earnings as Specialty Alloys Operations strength, pricing and higher shipments lift revenues, margins and operating income.
